These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 16775185)

  • 21. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
    Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
    Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lactase persistence, dietary intake of milk, and the risk for prostate cancer in Sweden and Finland.
    Torniainen S; Hedelin M; Autio V; Rasinperä H; Bälter KA; Klint A; Bellocco R; Wiklund F; Stattin P; Ikonen T; Tammela TL; Schleutker J; Grönberg H; Järvelä I
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):956-61. PubMed ID: 17507622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
    Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
    Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The MTHFR 677C --> T polymorphism and risk of prostate cancer: results from the CAPS study.
    Johansson M; Van Guelpen B; Hultdin J; Wiklund F; Adami HO; Bälter K; Grönberg H; Stattin P
    Cancer Causes Control; 2007 Dec; 18(10):1169-74. PubMed ID: 17846906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP1A1 polymorphisms and risk of prostate cancer: a meta-analysis.
    Shaik AP; Jamil K; Das P
    Urol J; 2009; 6(2):78-86. PubMed ID: 19472123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and cancer risk: the Croatian case-control study.
    Reljic A; Simundic AM; Topic E; Nikolac N; Justinic D; Stefanovic M
    Clin Biochem; 2007 Sep; 40(13-14):981-5. PubMed ID: 17573062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of MMP-1 1G/2G promoter gene polymorphism on the development of prostate cancer in the Turkish population.
    Albayrak S; Cangüven O; Göktaş C; Aydemir H; Köksal V
    Urol Int; 2007; 79(4):312-5. PubMed ID: 18025848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Haplotype-based analysis of common variation in the growth hormone receptor gene and prostate cancer risk.
    McKay JD; Kaaks R; Johansson M; Biessy C; Wiklund F; Bälter K; Adami HO; Boillot C; Gioia-Patricola L; Canzian F; Stattin P; Grönberg H
    Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):169-73. PubMed ID: 17220348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic variation in the SST gene and its receptors in relation to circulating levels of insulin-like growth factor-I, IGFBP3, and prostate cancer risk.
    Johansson M; McKay JD; Wiklund F; Rinaldi S; Hallmans G; Bälter K; Adami HO; Grönberg H; Stattin P; Kaaks R
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1644-50. PubMed ID: 19423539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer.
    Ahirwar D; Kesarwani P; Manchanda PK; Mandhani A; Mittal RD
    Cancer Genet Cytogenet; 2008 Jul; 184(1):1-8. PubMed ID: 18558283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. V89L polymorphism of the 5alpha-reductase Type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk.
    Boger-Megiddo I; Weiss NS; Barnett MJ; Goodman GE; Chen C
    Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):286-91. PubMed ID: 18268111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer.
    Fukuda H; Tsuchiya N; Narita S; Kumazawa T; Horikawa Y; Inoue T; Saito M; Yuasa T; Matsuura S; Satoh S; Ogawa O; Habuchi T
    Oncol Rep; 2007 Nov; 18(5):1155-63. PubMed ID: 17914566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth factor, cytokine, and vitamin D receptor polymorphisms and risk of benign prostatic hyperplasia in a community-based cohort of men.
    Mullan RJ; Bergstralh EJ; Farmer SA; Jacobson DJ; Hebbring SJ; Cunningham JM; Thibodeau SN; Lieber MM; Jacobsen SJ; Roberts RO
    Urology; 2006 Feb; 67(2):300-5. PubMed ID: 16461080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-6 promoter variants, prostate cancer risk, and survival.
    Tindall EA; Severi G; Hoang HN; Southey MC; English DR; Hopper JL; Giles GG; Hayes VM;
    Prostate; 2012 Dec; 72(16):1701-7. PubMed ID: 22782910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The H6D variant of NAG-1/GDF15 inhibits prostate xenograft growth in vivo.
    Wang X; Chrysovergis K; Bienstock RJ; Shim M; Eling TE
    Prostate; 2012 May; 72(6):677-89. PubMed ID: 21809352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Occurrence of NKX3.1 C154T polymorphism in men with and without prostate cancer and studies of its effect on protein function.
    Gelmann EP; Steadman DJ; Ma J; Ahronovitz N; Voeller HJ; Swope S; Abbaszadegan M; Brown KM; Strand K; Hayes RB; Stampfer MJ
    Cancer Res; 2002 May; 62(9):2654-9. PubMed ID: 11980664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The H6D genetic variation of GDF15 is associated with genesis, progress and prognosis in colorectal cancer.
    Wang J; Li W; Wang Y; Li C; Ding M; Zhang H; Lai M
    Pathol Res Pract; 2015 Nov; 211(11):845-50. PubMed ID: 26365480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer.
    Bauskin AR; Brown DA; Kuffner T; Johnen H; Luo XW; Hunter M; Breit SN
    Cancer Res; 2006 May; 66(10):4983-6. PubMed ID: 16707416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Advances in researches on the relationship between single nucleotide polymorphism and prostate cancer].
    Wang SK; Wang ZZ; Huang YF
    Zhonghua Nan Ke Xue; 2005 Aug; 11(8):605-10. PubMed ID: 16138582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues.
    Nakamura T; Scorilas A; Stephan C; Yousef GM; Kristiansen G; Jung K; Diamandis EP
    Br J Cancer; 2003 Apr; 88(7):1101-4. PubMed ID: 12671711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.